ide dismutase (ECSOD) by chondrocytes, affecting the level of antioxidant protection in joint tissue. Methods: Human cartilage explant cultures and primary monolayer cultures were used to assess the secretion of ECSOD in basal state and in response to IL-1 beta, with and without IL-1 receptor antagonist. ECSOD secretion was measured with an ELISA. Simultaneous determinations of nitrc oxide production were made using the greiss method. Results: IL-1beta decreases secretion of EC-SOD from chondrocytes both in explant and monolayer culture and treatment with both IL-1beta and IL-1 receptor antagonist together restores ECSOD secretion. As previously shown we find that IL-1 increases nitric oxide while treatment with IL-1 receptor antagonist reduces nitric oxide production.
. Mean EC-SOD secretion by human OA cartilage in vitro treated with IL-1beta. Conclusions: ECSOD scavenges superoxide and prevents oxidative damage in the joint. Cartilage tissue generates reactive oxygen species in response to cytokines and mechanical forces leaving the tissue vulnerable to oxidative damage. Chronic oxidative stress may increase cell senescence, cause damage to structural matrix proteins and alter cell signaling pathways leading to osteoarthritis. The finding that a key inflammatory cytokine (IL-1) decreases the available antioxidant protection in the joint may explain the progressive joint damage after inflammatory pathways are activated. Purpose: The aim of this study was to investigate if addition of bone morphogenetic protein (BMP)-2 to human articular chondrocytes (HACs) could help to maintain their chondrogenic phenotype in long-term culture conditions necessary for autologous chondrocyte implantation (ACI). We also evaluated the potential of BMP-2 as a repair factor in combination with collagen-based biomaterials, to extend the technique to osteoarthritic lesions. Methods and Material: In a first step, HACs from 19 donors were cultured independently, according to the procedure used for ACI. Real-time PCR and Western blotting were used to evaluate the chondrocyte phenotype and gel retardation assays were performed to analyze DNA binding of transcription factors under the effect of BMP-2. Next, we evaluated the responsiveness of HAC to BMP-2 when cultured within collagen sponges. This first approach was undertaken with independent cultures of three donors and the cellular phenotype was estimated by using real-time PCR. Results: Exogenous BMP-2 improved the chondrogenic character of HACs when amplified over two passages in monolayer. The stimulatory effect of BMP-2 on type II collagen expression was observed not only at the mRNA level but also at the protein level, and this is crucial for cartilage matrix reconstruction. Our preliminary data with HACs first amplified in monolayer then cultured in collagen sponges in the presence of BMP-2 have revealed that BMP-2 is able to restore COL2A1 gene expression that was lost during the amplification step. Conclusions: Adding exogenous BMP-2 to HACs expanded in the conditions generally used for ACI or during Matrix-associated ACI is clearly beneficial to support the chondrocytic phenotype. Importantly, no sign of hypertrophic maturation or osteogenic induction was detected beside the chondrogenic stimulatory effect of BMP-2. This study is the first to reveal the benefit of adding exogenous BMP-2 to HACs as a therapeutic agent for cartilage repair. Barts and The London Sch. of Med. and Dentistry, London, United Kingdom; 3 Royal Liverpool and Broadgreen Univ. Hosp. Trust, Liverpool, United Kingdom Purpose: Alkaptonuria (AKU) is a rare autosomal recessive condition re-
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